EP0675723A4 - Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse. - Google Patents

Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.

Info

Publication number
EP0675723A4
EP0675723A4 EP94905419A EP94905419A EP0675723A4 EP 0675723 A4 EP0675723 A4 EP 0675723A4 EP 94905419 A EP94905419 A EP 94905419A EP 94905419 A EP94905419 A EP 94905419A EP 0675723 A4 EP0675723 A4 EP 0675723A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonate
treating
bone loss
preventing bone
estrogen therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94905419A
Other languages
German (de)
English (en)
Other versions
EP0675723A1 (fr
Inventor
Donna T Whiteford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0675723A1 publication Critical patent/EP0675723A1/fr
Publication of EP0675723A4 publication Critical patent/EP0675723A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP94905419A 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse. Ceased EP0675723A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99641892A 1992-12-23 1992-12-23
US996418 1992-12-23
PCT/US1993/012302 WO1994014455A1 (fr) 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des ×strogenes en vue de traiter et de prevenir la resorption osseuse

Publications (2)

Publication Number Publication Date
EP0675723A1 EP0675723A1 (fr) 1995-10-11
EP0675723A4 true EP0675723A4 (fr) 1998-08-05

Family

ID=25542895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94905419A Ceased EP0675723A4 (fr) 1992-12-23 1993-12-17 Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.

Country Status (5)

Country Link
EP (1) EP0675723A4 (fr)
JP (1) JPH08505142A (fr)
AU (1) AU5953894A (fr)
CA (1) CA2151240A1 (fr)
WO (1) WO1994014455A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59300688D1 (de) * 1993-05-15 1995-11-02 Boehringer Mannheim Gmbh Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff.
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
NZ272608A (en) * 1994-07-22 2000-05-26 Lilly Co Eli Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
AU713824B2 (en) * 1995-05-12 1999-12-09 Merck Sharp & Dohme Corp. Prevention of tooth loss by the administration of alendronate or its salts
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
WO1997044017A1 (fr) * 1996-05-17 1997-11-27 Merck & Co., Inc. Formulation de bisphosphonate efferverscente
EP1378234A1 (fr) * 1996-05-17 2004-01-07 MERCK & CO. INC. Formulation de bisphosphonate effervescente
EP0949928A4 (fr) * 1996-11-25 2000-09-13 Merck & Co Inc Agents androgene et bisphosphonique coadministres pour traiter des maladies
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
DE19719680A1 (de) * 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
CA2281937A1 (fr) * 1997-12-25 1999-07-08 Toray Industries, Inc. Medicament pour traiter les anormalites de moelle osseuse
CA2353528C (fr) * 1998-12-04 2007-04-24 Roche Diagnostics Gmbh Utilisation d'ibandronate pour favoriser l'osseointegration des endoprotheses
AU4652100A (en) * 1999-04-22 2000-11-10 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
FR2803521B1 (fr) 2000-01-12 2002-10-25 Ceva Sante Animale Utilisation de l'acide tiludronique et de ses derives chez la volaille pour la preparation d'un medicament destine a prevenir et a traiter l'osteoporose
SI1365769T1 (sl) * 2001-02-06 2011-06-30 Sydney Children S Hospitals Network Randwick And Westmead Incorporating The Royal Alexandra Hospital Zdravilo za zdravljenje osteonekroze za oskrbo pacientov pri tveganju razvoja osteonekroze
EP1383509A4 (fr) * 2001-04-03 2005-10-26 Royal Alexandra Hosp Children Medicament a utiliser en matiere de greffe osseuse
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
BR0215413A (pt) 2001-12-24 2004-12-14 Teva Pharma Formula dosada com um comprimido central de ingrediente ativo encapado em uma capa anular prensada de material em pó ou granulado e processo e conjunto de ferramentas para a sua produção
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1508343B1 (fr) * 2003-08-21 2015-11-04 AddBIO AB Implant revêtu de bisphosphonate et son procédé de fabrication
EP1940339B1 (fr) * 2005-10-27 2011-12-21 Thommen Medical Ag Implant dentaire et procede de fabrication
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005187A1 (fr) * 1990-09-18 1992-04-02 Boehringer Mannheim Gmbh NOUVEAUX DERIVES DE 17-β-OESTRADIOL, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS CONTENANT CES COMPOSES
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
WO1992014474A1 (fr) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Procede de traitement de l'osteoporose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005187A1 (fr) * 1990-09-18 1992-04-02 Boehringer Mannheim Gmbh NOUVEAUX DERIVES DE 17-β-OESTRADIOL, LEUR PROCEDE DE PRODUCTION ET MEDICAMENTS CONTENANT CES COMPOSES
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
WO1992014474A1 (fr) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Procede de traitement de l'osteoporose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIMINERA N. ET AL: "Studio Comparativo degli effeti di estrogeni e difosfonati sulla perdita ossea postmenopausale", ANN. OSTET. GINECOL. MED. PERINAT., vol. 113, no. 5, 1992, pages 232 - 237, XP002064831 *
See also references of WO9414455A1 *

Also Published As

Publication number Publication date
JPH08505142A (ja) 1996-06-04
AU5953894A (en) 1994-07-19
WO1994014455A1 (fr) 1994-07-07
CA2151240A1 (fr) 1994-07-07
EP0675723A1 (fr) 1995-10-11

Similar Documents

Publication Publication Date Title
EP0675723A4 (fr) Therapie utilisant des bisphosphonates et des strogenes en vue de traiter et de prevenir la resorption osseuse.
GB9411080D0 (en) Treatment
ZA95556B (en) Combination treatment for osteoporosis
AP9300539A0 (en) Steroidal glycosides for treating hypercholest erolemia
IL115310A0 (en) Combination therapy for hypercholesterolemia
EP0589252A3 (fr) Méthode d'induction de fibrillation dans des dispositifs implantables.
AP2002002661A0 (en) Combination therapy for oesteoporosis
IL115582A0 (en) Methods for treating resistant tumors
IL122149A0 (en) Bisphosphonates preventing bone loss associated with immunosuppressive therapy
GB2296108B (en) Tractor and machine combination and control system therefor
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
GB9303210D0 (en) Cancer treatment
GB9215042D0 (en) Microwave treatment apparatus
IL108197A0 (en) Pharmaceutical composition for preventing or treating arterioscleriosis
EP0650372A4 (fr) Composes destines a la visualisation et a la therapie du cancer.
HU9402578D0 (en) Medicament for treating or preventing cerebrovascular diseases
ZA942809B (en) Treatment
GB9315275D0 (en) Formulation for treating silage
GB9217124D0 (en) Medical treatment
EP0839032A4 (fr) Ions hydroxyle a titre d'agents therapeutiques particuliers, et composes aptes a moduler ces ions, composes
PL320564A1 (en) Therapeutic set for treating osteoporosis
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
HK1021946A1 (en) Electromagnetic therapeutic treatment device.
EP0662782A4 (fr) Therapie a base de pp14.
GB9313550D0 (en) Bone implant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980619

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20031106

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009249

Country of ref document: HK